ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1285

Short-Term Efficacy of Etanercept Plus Methotrexate Vs.Various Disease-Modifying Anti-Rheumatic Combinations with Methotrexate in Established Rheumatoid Arthritis

Roy Fleischmann1, Andrew S. Koenig2, Annette Szumski3, Henk Nab4, Lisa Marshall5 and Eustratios Bananis3, 1University of Texas Southwestern Medical Center, Dallas, TX, 2Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, 3Specialty Care, Pfizer Inc., Collegeville, PA, 4Pfizer Europe, Rome, Italy, 5Pfizer Inc., Collegeville, PA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: DMARDs, etanercept, methotrexate (MTX) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: The objective of this study was to assess the short-term benefit of etanercept (ETN) + methotrexate (MTX) vs. various disease-modifying anti-rheumatic drugs (DMARDs; hydroxychloroquine [HCQ], leflunomide [LEF], or sulfasalazine [SSZ]) + MTX in subjects with established rheumatoid arthritis (RA).

Methods: Data from subjects with moderate-to-severe RA and an inadequate response to MTX were pooled from the APPEAL1 (ETN 25 mg twice weekly + MTX or DMARD + MTX) and LatinRA2, 3  (ETN 50mg once weekly + MTX or DMARD + MTX) studies. At week 16, proportions of subjects for each pair of treatments were compared using Fisher’s exact test for the following endpoints: American College of Rheumatology (ACR) 20, 50 and 70 responses, disease activity score in 28 joints (DAS28, both C-reactive protein [CRP; DAS28-CRP] and erythrocyte sedimentation rate [ESR; DAS28-ESR] methods) low disease activity (LDA; DAS28-CRP or DAS28-ESR ≤3.2), remission (DAS28-CRP or DAS28-ESR <2.6), Clinical Disease Activity Index (CDAI) of LDA (CDAI ≤10), CDAI remission (CDAI <2.8), and a Health Assessment Questionnaire (HAQ) score of ≤0.5.

ACR APPEAL LARA.jpg

Results: 478 subjects received ETN + MTX and 245 subjects received a DMARD + MTX (HCQ + MTX, n=81; LEF + MTX, n=69; SSZ + MTX, n=95). Baseline demographics were similar between the 2 treatment groups, with a mean age of 48.5 years (standard deviation [SD], 11.7; p=0.983) and disease duration of 7.6 years (SD, 7.5; p=0.437). At week 16, significantly more subjects receiving ETN + MTX achieved ACR 20/50/70, DAS28-CRP LDA and remission, DAS28-ESR LDA and remission, CDAI LDA and remission, and HAQ ≤0.5 compared with subjects on DMARDs + MTX (Table). Significantly greater proportions of subjects in the ETN + MTX group vs. the HCQ + MTX, LEF + MTX, and SSZ + MTX groups reached these endpoints with the exception of CDAI remission for all DMARD types and DAS28-CRP LDA, DAS28-ESR remission, CDAI LDA, and HAQ ≤0.5 in the LEF + MTX group. In addition, significantly more subjects on LEF + MTX achieved ACR50, DAS28-CRP LDA, DAS28-CRP remission, and CDAI LDA than subjects on SSZ + MTX.

Conclusion: Combination ETN + MTX was more effective in treating subjects with established moderate-to-severe RA regardless of the DMARD combination (HCQ, LEF, or SSZ) + MTX. LEF + MTX and HCQ + MTX had some greater benefits over SSZ + MTX at 16 weeks.

References

1. Kim HY et al. Int J Rheum Dis 2012;15:188-96.

2. Machado D et al. Pan American League of Associations for Rheumatology 2012; Poster.

3. Javier R et al. Pan American League of Associations for Rheumatology 2012; Poster.

 


Disclosure:

R. Fleischmann,

Research grants: Genentech Inc, Roche, Abbott, Amgen, UCB, Pfizer Inc, BMS, Lilly, Sanofi Aventis, Lexicon, MSD, Novartis, BiogenIdec, Astellas, Astra-Zeneca, Janssen,

2,

Roche, Abbott, Amgen, UCB, Pfizer, BMS, Lilly, Sanofi Aventis, Lexicon, Novartis, Astellas, Astra-Zeneca, Janssen, HGS,

5;

A. S. Koenig,

Pfizer Inc,

3;

A. Szumski,
None;

H. Nab,

Pfizer Inc,

1,

Pfizer Inc,

3;

L. Marshall,

Pfizer Inc,

3;

E. Bananis,

Pfizer Inc,

3.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/short-term-efficacy-of-etanercept-plus-methotrexate-vs-various-disease-modifying-anti-rheumatic-combinations-with-methotrexate-in-established-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology